Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours: A collaboration with the European Innovative Therapies for Children with Cancer Network

Published:2020-08 Issue: Volume:135 Page:89-97
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Amoroso Loredana,Castel Victoria^ORCID,Bisogno Gianni,Casanova Michela,Marquez-Vega Catalina,Chisholm Julia C.,Doz François,Moreno Lucas^ORCID,Ruggiero Antonio,Gerber Nicolas U.,Fagioli Franca,Hingorani Pooja,Melcón Soledad G.,Slepetis Ruta,Chen Nianhang,le Bruchec Yvan,Simcock Mathew,Vassal Gilles

Funder

Bristol-Myers Squibb Company, Princeton, NJ

Jazz Pharmaceuticals

Bristol-Myers Squibb

Celgene

Novartis

MundiPharma

Amgen

Bristol-Myers Squibb Company

National Health Service

Instituto de Salud Carlos III

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference26 articles.

1. Cancer facts & figures 2018,2018

2. Causes of death among children aged 5-14 years in the WHO European Region: a systematic analysis for the Global Burden of Disease Study 2016;Kyu;Lancet Child Adolesc Health,2018

3. Survival after recurrence of Ewing's sarcoma family of tumors;Barker;J Clin Oncol,2005

4. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project;London;J Clin Oncol,2011

5. Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group;Pappo;J Clin Oncol,1999

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the future;Medicinal Research Reviews;2024-06-17

2. A pediatric and young adult case of unclassified renal cell carcinoma with medullary phenotype (RCCU-MP): Clinical course and treatment;Journal of Onco-Nephrology;2024-05-08

3. EGCG Disrupts the LIN28B/Let-7 Interaction and Reduces Neuroblastoma Aggressiveness;International Journal of Molecular Sciences;2024-04-27

4. Angiosarcoma in children: the experience of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology and literature review;Pediatric Hematology/Oncology and Immunopathology;2023-12-20

5. Numbers Matter: The Role of Cell Dose in the Treatment of Osteosarcoma Using Mesenchymal Stromal Cells as Cellular Vehicles;Advanced Therapeutics;2023-07-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3